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Dynamic Model of Nonmedical Opioid Use Trajectories and
Potential Policy Interventions
Wayne Wakeland, Alexandra Nielsen, and Peter Geissert
Portland State University, Portland, OR

Abstract
Background—Nonmedical use of pharmaceutical opioid analgesics (POA) increased
dramatically over the past two decades and remains a major health problem in the United States,
contributing to over 16,000 accidental poisoning deaths in 2010.
Objectives—Create a systems oriented theory/model to explain the historical behaviors of
interest, including the various populations of nonmedical opioid users and accidental overdose
mortality within those populations. Use the model to explore policy interventions including tamper
resistant drug formulations and strategies for reducing diversion of opioid medicines.
Methods—A system dynamics model was constructed to represent the population of people who
initiate nonmedical POA usage. The model incorporates use trajectories including development of
use disorders, transitions from reliance on informal sharing to paying for drugs, transition from
oral administration to tampering to facilitate non-oral routes of administration, and transition to
heroin use by some users, as well as movement into and out of the population through quitting and
mortality. Empirical support was drawn from national surveys (NSDUH, TEDS, MTF, and
ARCOS) and published studies.
Results—Model was able to replicate the patterns seen in the historical data for each user
population, and the associated overdose deaths. Policy analysis showed that both tamper resistant
formulations and interventions to reduce informal sharing could significantly reduce nonmedical
user populations and overdose deaths in the long term, but the modeled effect sizes require
additional empirical support.
Conclusion—Creating a theory/model that can explain system behaviors at a systems level scale
is feasible and facilitates thorough evaluation of policy interventions.

Introduction
The dramatic increase in nonmedical use of pharmaceutical opioid analgesics (POAs) in the
late 1990’s and early 2000’s created an enduring public health challenge for the United
States (1). Despite implementation of public health policies and regulations (2), and
stabilization of nonmedical POA use (3), the prevalence of negative outcomes, including
POA-related overdose deaths, persists (4).
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POAs reach consumers through a complex delivery system comprised of many interacting
agents: prescribers, patients, people using opioids non-medically, family, and peers. These
interactions occur in the context of a policy environment that encompasses laws, regulations,
public health policy interventions, and enforcement efforts. In highly connected systems of
this nature feedback mechanisms may exist that have the potential to perversely diminish,
neutralize or even reverse the influence of interventions (5).
This article presents an exploratory system dynamics simulation model of the complex
system surrounding the initiation and nonmedical use of POAs in the United States and the
drug use trajectories of people who use POAs nonmedically. In addition to fitting the model
to historical trends, the model aims to increase understanding of the complex interactions
and underlying processes that give rise to this major public health concern, to identify gaps
in the published literature, and to allow for experimentation with policy options.

Background
Prescriptions for POAs increased 10 fold over the last two decades (6). A number of factors
contribute to this trend including changing standards and guidelines for treatment of pain,
changes in drug formulation, and demographic changes (7,8). This increase occurred in
parallel with a rise in nonmedical use of POAs. The 2012 National Survey on Drug Use and
Health reports that an estimated 1.9 million individuals initiated nonmedical POA use and
4.9 million individuals used POAs nonmedically within the month prior to the survey (3).
The estimated number of people using POAs non-medically in the past 12 months has
remained fairly stable since 2002: between 4–5% of the US population (3).
Despite the relative stability of the prevalence of non-medical use of POAs, negative
outcomes associated with prescription drug use have continued to rise. Treatment
admissions for POAs increased six-fold from 1998 to 2008 (9), emergency department visits
involving prescription opioids increased by 153% between 2004 and 2011 (10), and POArelated poisoning deaths increased more than four-fold to 16,651 between 1999 and 2010
(11).
A number of supply-side interventions have been implemented in an attempt to curtail POA
abuse and negative outcomes. These include continuing education for clinicians and other
FDA-mandated Risk Evaluation and Mitigation Strategies (2), pill take-back programs
(12,13), prescription drug monitoring programs (14), and tamper-resistant pills (15,16).
Tampering refers to crushing or dissolving a pill in order to snort or inject it. Concern has
arisen that faced with supply restriction, people dependent on POAs may switch to heroin
because of its similarity to POAs. Anecdotal reports and emerging research suggest that this
may be occurring.
Several qualitative studies clearly identify a drug use trajectory that includes initiation to
POAs and later transition to heroin (17–19). However, these studies have small sample sizes
and estimates of prevalence based on them may not be generalizable. Two studies have
reported that a high proportion (65–73%) of heroin users reported use of POAs prior to
heroin initiation (20,21). Surveys conducted among intravenous heroin users performed in
San Diego, Portland and Seattle provide further evidence of this phenomenon: between 39–
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47% of respondents 18–40 years of age reported having been “hooked on” POAs before
initiating heroin use (22–24). Studies among heroin users with a history of prescription
opioid abuse suggest a number of factors influencing transition from POAs to heroin.
Respondents have reported that heroin is cheaper (18,20,21,25), more effective (20), gives a
better high (21), and is easier to access (21).
Tamper resistant formulations (that make pills harder to crush or dissolve) of extended
release opioids may serve to reduce non-oral abuse (26); however, it is not clear what the
long term impacts of this intervention will be, nor how the drug use trajectories of POA
users might be impacted by policies that produce scarcity of abusable POAs. System
dynamics modeling offers a method that leverages existing research in order to explore the
behavior of the prescription drug delivery system under circumstances of supply restriction
and thereby help to explain historical trends and evaluate the consequences of policy
changes.

Method
System dynamics modeling
Policy decisions should be made on the basis of the best available evidence (27). Under the
best circumstances evaluation studies are available that look at the efficacy of similar policy
changes enacted in other settings. At times the evidence evaluating an intervention or
proposed policy may be limited or non-existent, so decisions must be based on existing
related research and general domain knowledge. Research in the policy arena has the dual
purpose to provide an evidence base for policy decisions (the problem solving function) and
a tool for explanation and communication (the enlightenment function) (28). Depending on
the policy domain these two roles may be of greater or lesser importance. The behavior of
systems that feature feedback among endogenous variables and non-linearity is less
intuitive, and thus the explanatory/knowledge translation role of research becomes more
important.
Every policy intervention contains an implicit causal hypothesis. The policy maker proposes
that the policy change will initiate a chain of causal events that will result in a desired
outcome. The challenge of policy making lies in having a sufficient understanding of the
underlying processes at work. It can be difficult to estimate the range of probable outcomes
of a policy change based on existing research and domain knowledge. Academic research
often provides a fine-grained view of specific local conditions and estimates the
relationships between a number of variables and a dependent variable. When a policy is
enacted the outcome may be dependent on a chain of events compounded over time.
Feedback mechanisms may lead to counter-intuitive results. Cognitively we are not well
equipped to develop mental models of systems that involve complex highly interdependent
sets of variables that change over time.
System dynamics modeling is a tool that allows us to augment our mental models by making
the network of relationships that comprise a system manifest in an influence diagram (cf, 5,
29). The influence diagram is a graphical model that provides a high level view of the
system. Elements of the model are represented as constants, auxiliary variables (functions),
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stock variables, and flows (rates). System dynamics models offer an analytical platform for
calculating and visualizing the behavior of the modeled system over time (ibid). The
behavior is simulated through time by numerical integration of differential equations for the
rates of change of the stock variables. System dynamics is often used to study health issues
(cf 30, 31, 32, 33).
This type of modelling has several benefits. First, it provides a broad view of the structure of
a system that can help explain the underlying processes and feedback loops that generate
complex behavior. Second, it can be used to simulate complex feedback relationships that
have no analytical solution. Third, the process of constructing such a model provides an
opportunity to assess the gaps in our knowledge. System dynamics models require estimated
values for all salient components of the system, and empirical support is drawn from many
different sources in the literature and from public data sets. In constructing the model,
speculative assertions become stated assumptions and limitations, and may be subjected to
greater scrutiny and sensitivity testing, including tests to determine which model parameters
most strongly influence model behavior and therefore must be estimated as precisely as
possible with the best available data and statistical methods.
Model development
System dynamics modeling is comprised of a number of distinct stages (5). Specification of
a model defines the overall structure of the dynamical system. Calibration is the fitting of
parameter values for the model. Validation is the comparison of model performance to a
reference behavior pattern- a new data set that was not used in specifying or calibrating the
model.
Developing a system dynamics model has both qualitative and quantitative components. Our
model specification process began with interviews with our expert advisory panel- a group
of four researchers and practitioners with domain knowledge in the areas of pain medicine
(n=2), pharmaceutical abuse liability (n=3), substance abuse (n=2), public health (n=3), and
health economics (n=1). The qualitative understanding gained from these interviews
provided the initial influence diagram depicting the qualitative connections among variables
of interest. This diagram was presented back to the advisory panel to be evaluated for face
validity, literally whether the model is consistent with their domain knowledge and
understanding of the system. Updates and amendments were made per their
recommendations.
Once the structure of the model was established, a literature review was conducted to locate
sources of empirical support for the relationships represented in the model. At this stage in
the modeling process the wealth of research in the field becomes the raw data used to
calibrate a model. Research from the large body of published literature was synthesized to
estimate parameter values. When estimates of incidence from cohort studies or measures of
correlation are in the right form they can be used to provide direct empirical support for a
parameter, otherwise a parameter value may be estimated indirectly.
Best practices in simulation research require that the conceptual structure of a simulation be
driven by the research question rather than data availability (34).Thus, it is inevitable in
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simulation studies that not all parameters or structural relationships can be fully supported
empirically (35). In this study, where empirical support was lacking experts were consulted,
proxy measures were employed, and parameters were defined through model calibration.
The model was implemented in Vensim (36), the industry standard system dynamics
software (cf 5, 27, 29) and calibrated to reproduce historical behavior. Large national
surveys and data sets—the National Survey on Drug Use and Health (NSDUH), Treatment
Episode Data Set (TEDS), Monitoring the Future (MTF), and the Automation of Reports
and Consolidated orders System (ARCOS) —provided data against which the results of the
model could be compared. System dynamics models can be highly sensitive to initial
conditions for stock variables, and while reliable data are available for some of the stock
variables, others had to be estimated as part of the calibration process. Once calibrated,
mean percentage error between model-calculated values and reference data was 8–12% for
the # of people initiating POA misuse, # of POA misusers, # of heroin users, POA deaths,
and heroin deaths (see Figures 4, 6, and 7 for details. These errors were judged to be small
enough to warrant proceeding to use the model to explore and compare policy interventions.
This article describes three supply-side interventions—introducing tamper resistant
formulations, reducing medicine sharing via patient education or smaller prescription sizes,
and implementing drug take-back days.
Model structure and logic
Figure 1 provides a high level picture of model structure which highlights the feedback
processes at work in the system. Feedback processes exist when outcomes end up
influencing inputs, resulting in circular rather than linear causality. Fundamentally, the POA
story is as follows: POA misuse follows a trajectory in which people may initiate
nonmedical use, may transition to paying for opioids and tampering with them, and finally
may transition to heroin use.
The POA drug misuse trajectory is influenced by the availability, accessibility, and physical
properties of the POA supply; and at any point in the trajectory, people may quit or die. To
aid in understanding the entire model with its multiple feedback loops, we focus on its
sectors: peer initiation, global availability, personal accessibility, and transition to tampering
and heroin use. The description of each sector includes an outline of empirical support, a
narrative description of model elements and structure, and a simplified influence diagram. A
full model diagram is provided as a supplemental figure.
Peer Initiation
Empirical studies endorse peer influence, exposure via legitimate prescription, and social
exposure as factors in drug use initiation (19,37). These recruitment mechanisms, shown in
Figure 2, are modeled using a “susceptible, infected, recovered” (SIR) epidemic framework
(5). In SIR epidemic models, an infected person interacts with susceptible individuals based
on a contact rate. The infectivity of the disease is the likelihood that contact results in
infection. When the number of infected individuals becomes large, members of the
susceptible group are likely to have multiple contacts with infected people, and the rate of
infection grows, resulting in an epidemic.
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The SIR model framework can also be applied to peer initiation processes (5). In this
instance, susceptible individuals are those who have never used opioids nonmedically. When
susceptibles interact with Recreational Users (Using Free Opioids), the idea of using opioids
recreationally may spread. After exposure, the susceptible person may initiate POA use
depending on the how compelling the idea is—its “infectivity.” An increase in the number
of Recreational Users increases the rate of initiation, further increasing the number of
Recreational Users, and so on. This type of growth process is known as a reinforcing
feedback loop.
In the typical SIR infectious disease model, people who recover from infection are not
susceptible to reinfection nor do they spread the disease. Similarly, in the present model, not
all nonmedical POA users participate in the peer recruitment process that influences
susceptibles to initiate nonmedical usage. Once a misuser develops a use disorder and begins
using more than he or she can obtain for free, this person is assumed not to interact
significantly with susceptibles (38–40). Use disorder is associated with frequency and/or
intensity of use, and could involve the normal oral route of administration (ROA) or snorting
or intravenous injection. These other ROAs require tampering with the pills to crush them or
dissolve them. Users with use disorder include Oral ROA Paying Users, and Tampering
ROA Paying Users in Figure 1.
Global Availability
To initiate POA use, a susceptible must have exposure to the idea of POA use and have
access to POAs. Figure 3 describes the relationship between the supply of free POAs in
medicine cabinets, and the progression of users from casual use of free POAs, to
development of a use disorder, to paying for POAs.
Informal sharing of POAs is the source of POAs for the majority of nonmedical users; 70%
of respondents to the 2010 NSDUH indicated that they received POAs from friends or
relatives (41). A recent study of people who use POAs nonmedically found that most
individuals did not have to venture outside of their social networks to find people who
would share pills (42). Leftover medicine from prescriptions are likely implicated in
diversion (43). Diversion refers to medicines being made available for nonmedical use.
Another study found that 42% of POAs prescribed were not consumed, 67% of patients had
leftover medicine, and 91% of the patients with leftover medicine did not dispose of it (44).
A recent survey of college students found that 35% had diverted POAs (45).
The outermost arrows in Figure 3 represent the global dynamics of opioid availability: much
of the leftover POA supply is not accessible because prescription holders may have no
desire to use POAs nonmedically or know anyone who does. As the population of
Recreational Users seeking free POAs increases (boxed variables at the bottom of Figure 3),
the likelihood that a prescription holder will be approached by at least one friend requesting
free diverted POAs increases dramatically. Some fraction of prescription holders approached
will choose to share. Their leftover medicine becomes “Available Free POA Medicine
Cabinet” supply (boxed variable at the top of Figure 3). In short, increased initiation leads to
increased accessibility of leftover POAs which further increases initiation and the
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population of Recreational Users and “opens up” more sharing. This completes a second
reinforcing feedback loop.
Personal accessibility
Frequent use of pharmaceutical opioids can lead to the development of opioid use disorders
(46) and consumption levels that cannot be sustained by free leftover medicines prescribed
to those in one’s personal network. Research indicates that students who screened positive
for a substance use disorder were more likely to buy POAs and obtain them from multiple
sources (47) and that paying money for POAs was associated with more frequent use (42).
The inner arrows shown in Figure 3 also show the local dynamics of opioid availability,
which operate differently than the global dynamics. A fraction of Free Users Without Use
Disorder develop an opioid use disorder (Free Users With Use Disorder in Figure 3). These
users exhaust the free supply of opioids accessible in their social networks and may
transition to paying for POAs. Although increasing the number of people using free POAs
further opens up supply globally, increased consumption by Free Users With Use Disorder
reduces free supply of POAs locally. Consequently, Transitioning to Paying for Opioids
increases and Free Users With Use Disorder decreases. In short, as the increase in available
medications results in more use disorder, individual availability is diminished resulting in
individuals transitioning to paying for pills. These individuals no longer participate in the
peer influence process resulting in a decrease in availability and initiation. This type of selflimiting process is referred to as a balancing feedback loop.
Transition to tampering and heroin use
The literature on the association between paying for POA and tampering is sparse, but a
recent study found that people who pay for POA are 1.5 times more likely to snort POAs
(42). While most recreational users use the oral ROA (40), most experienced abusers tamper
with POAs to increase the subjective effects (49–51). Length of time abusing POAs and use
disorders are associated with higher prevalence of non-oral ROAs (51,52). A study of people
abusing POAs found that those who also used heroin were less likely to use POA orally and
more likely to snort, smoke or inject POAs (53). People who transition from POAs to heroin
give many reasons for doing so, including inability to access their POA of choice (21).
While many heroin users first initiated POAs (17,20,21,23,24), this is not always the case. A
recent cohort analysis showed that older heroin abusers tended to initiate heroin use before
POA use (54).
In the model, people who pay for POAs fall into two groups, Oral ROA Paying Users and
Tampering ROA Paying Users (see Figure 1). Paying users begin with oral ROA and may
transition to tampering, and of those who tamper with POAs some may transition to heroin
use. The model assumes that transition directly from oral abuse to heroin use is negligible,
consistent with empirical studies (53). Transition from Tampering ROA Paying Users to
Heroin Users increases when trafficked supply of POAs decreases. Trafficked means a
“dealer” is involved and drugs are paid for with money or trade. Trafficked supply
availability is an exogenous input to the model that was derived from a dynamic model of
medical POA use and trafficking (55), and is consistent with anecdotal evidence reported in
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the popular press (e.g. 56). Other pathways to heroin use are modeled simply as a single
additional inflow to the heroin user population.

Model Calibration and Testing
Making a computational version of the model could be viewed as creating an elaborate
“theory” for how the system actually “works.” Calibrating the model to endogenously
reproduce the dynamic behaviors of this complex nonlinear system at multiple points
(number of new users per year, user population levels, and overdose deaths) is not an easy
task, and therefore, once it has been shown that the theory/model can in fact reproduce these
reference behaviors, the the model can be considered ready to be used to explore policy
options. In the section that follows, we first show the comparisons of model-calculated
behavior to reference data, and then report policy analysis results.
Comparison of model-calculated results to reference data
Beginning with the initiation process, Figure 4 shows the number of model-calculated new
initiates and Recreational (using Free Opioids) Users compared to data from the annual
NSDUH survey.
Figure 5 shows the number of nonmedical users with use disorder at each stage of the
progression: Free Users with Use Disorder, Oral ROA Paying Users, and Tampering ROA
Paying Users.
The final user transition represented in the model is from Tampering ROA Paying Users to
Heroin Users. Figure 6 shows model-calculated populations versus reference data for the
number of POA users with use disorder (total of the populations in Figure 5) and for Heroin
Users.
Figure 7 shows model calculated deaths associated with nonmedical POA use and with
heroin use compared to reference data. In order for the model to accurately calculate death
figures consistent with reference data, it was necessary to incorporate a multiplier
representing increasing mortality rates over time (from 1 prior to 2000, to 2.5 in 2011 and
later). This ramp up is primarily attributed to a trend toward increased usage of multiple
drugs (poly drug use) by all categories of nonmedical users (49,50), and an increase in the
proportion of high dosage opioid users.
Exploration of policy interventions
Once the model had been calibrated to reproduce reference behavior, it was used to explore
the impact of policies implemented in mid-2010 and evaluated over the period from 2011 to
2016 since it can take several years for the even short-term impacts of policy changes to
manifest.
Tamper resistant drug formulations—A very simple analysis was done to assess the
effectiveness and potential side effects that might result from the introduction of tamper
resistant (TR) formulations of POAs. We assume that tamper resistant formulations do not
significantly impact Recreational Users who tend to take the pills orally (48), and relatively
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infrequently (34). We also assume that transition from oral use of POAs directly to heroin is
negligible (53). Given these assumptions, it follows that the main effects of TR would be to
inhibit the transition from oral use to tampering with POAs and to accelerate the transition
of Tampering ROA Paying Users to heroin use. The degree of inhibition and the degree of
acceleration are inversely related and symmetric: if half the POAs are TR, then transition to
tampering is reduced by a factor of two and transition from tampering to heroin is doubled.
The rollout of TR POAs was modeled very simply as the fraction of POAs that are tamper
resistant, which increases over time. The fraction is zero prior to the middle of 2010, when a
TR formulation of Oxycontin® was first introduced (26). In order to cut the number of
Tampering ROA Paying Users in half by 2016, the upper limit was set to 70% over the sixyear policy exploration period. Table 1 shows projected changes in Paying Users and heroin
users, and the impact on overdose deaths.
Assuming it is true that nonmedical users with use disorder are likely to either remain oral
abusers or switch to heroin, the net benefits in terms of accidental deaths would seem to be
modest overall—perhaps 1000 lives saved. The population of Tampering ROA Paying Users
is quickly reduced. Many switch to heroin in the short term, but the effect is transitory. Once
the population of Tampering ROA Paying Users declines, the flow from tampering to heroin
is also reduced. The population of Oral ROA Paying Users increases in this scenario because
fewer oral users transition to tampering. The overdose (OD) mortality rate for oral users is
assumed to be lower (59), so a decrease in mortality is expected.
Informal sharing supply interventions
Two policy interventions focused on reducing informal sharing were then tested: 1)
removing 100 million dosage units of POAs available for nonmedical use per year through
drug take-backs, and 2) reducing sharing of leftovers by 50%. The magnitudes of each
policy scenario were selected to illustrate plausible upper limits for the potential impact
rather than realistic implementation scenarios. DEA drug take back events have collected
about 503 tons (roughly 10 billion pills) of unwanted medicine per year since 2010 (60).
Gray and Hagemeier (2012) found that 10% of disposed medicines were controlled
substances at take back events in Appalachian areas (12). If just 1% of all disposed
medicines were POAs, then removal of 100 million dosage units of POAs from the free
nonmedical POA supply per year would be quite feasible.
The amount of leftover medicine per prescription could be reduced after the fact by
educating patients about risks, safe storage, and safe disposal, or at the point of prescription
by shortening the length of prescriptions, restricting refills, and/or reclassifying medicines
such as hydrocodone from Schedule III to Schedule II (61). Two parameters in the model
are relevant; the “fraction who might share” and the “typical leftover percentage” (see
Figure 3). We model a 50% reduction in new leftovers becoming available for nonmedical
use by reducing each parameter by 25%. Unfortunately, to date no studies have been
published on the impact of patient centered interventions on medication sharing (62), so the
modeled magnitude of impact is speculative. Figure 8 shows how such a change in informal
sharing of leftovers and drug take backs impact the nonmedical POA user populations in the
model.
Am J Drug Alcohol Abuse. Author manuscript; available in PMC 2015 December 21.
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As shown in Figure 8, model results suggest that reducing the fraction of people willing to
share and/or the amount of leftover medicine could significantly reduce user populations
over time. Patient education and drug take-backs days appear to have nearly the same
potential. Table 2 provides additional details, including the likely impact on overdose
deaths. Although the effect on the population of Tampering ROA Paying Users is small, it
does begin to shrink by the end of the policy period as reduced initiation upstream reduces
all of the user populations eventually. During most of the policy period, however, the
number of Tampering ROA Paying Users is elevated because in the near term supply
restriction drives people with use disorder to paying for POAs and risker behaviors.
Cumulative OD deaths for this population over the policy period rise slightly above
baseline.
Combining tamper resistant formulations and reduced informal supply in the model leads
essentially to the two sets of benefits being added together, since the interventions mostly
impact different populations. Another possible strategy could be to combine policies to
reduce sharing/leftovers with drug take-back programs. The model shows that if both
interventions were successfully implemented, but at half of their presumed standalone
effectiveness, the net impact would be comparable. A potential benefit of such a strategy
could be to avoid the diminishing returns that might tend to plague a single-pronged
strategy.

Discussion
Although the model logic for the tamper resistant (TR) drug formulation analysis was
defined in an abstract fashion, it may in fact approximate how the intervention is being
implemented—as a linear increase over a several-year period. There are many POA
products, and pharmaceutical companies are working to develop and gain approval for new
TR formulations (63). This process takes time. While TR formulations significantly reduce
tampering of POAs, a major policy concern is possible “balloon effects” users changing
their ROA, or switching to other drugs, especially heroin. In the model, heroin use does
increase, though perhaps less than might be expected (+10%); the larger effect is on Oral
ROA Paying Users (+22%). Thus, the net result for the TR policy is quite modest--a 6%
reduction in OD deaths amongst the affected populations over the policy period. Another
reason for the modest impact is that the TR policy as modeled does not reduce OD deaths
associated with the largest population of nonmedical POA users (and therefore is not shown
in Table 1) Recreational Users. Recreational Users are subject to OD mortality risk and
these users account for 47% of the total OD deaths in the baseline model for the 2011–2016
policy period. We assume that TR formulations do not impact these users appreciably
because the overwhelming majority take the pills orally (59,64). Unless TR formulations
could somehow reduce OD mortality risk for recreational users who do not tamper with
POAs, the rate of ODs in this population may remain unchanged. This may explain in part
why actual OD deaths have continued to rise despite the introduction of multiple TR POA
products including OxyContin® and Opana®.
Our analysis suggests that reducing leftover medicines could reduce all nonmedical POA
user populations and OD deaths in the long run, to a greater degree than tamper-resistant
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drug formulations. Our model, in concordance with results from an analysis of NSDUH
survey data conducted by Jones (2012), supports a cohort theory for the increase in negative
outcomes (65). The dramatic increase in nonmedical POA initiation witnessed in the late
nineties and early 2000s resulted in lagged increases in dependence, transition to tampering
or heroin use, and OD deaths. Interventions that discourage initiation of nonmedical or
support early quitting have high leverage precisely because they result in lagged reductions
in all nonmedical user populations including those with high risk of OD death. To date the
effectiveness of policies to reduce leftovers and the impact on nonmedical POA use have not
been systematically studied and remain speculative, whereas tamper resistant formulations
have already reached the market and post-marketing surveillance results are encouraging if
not conclusive (26, 66, 67). However, since this intervention primarily reduces risks for
nonmedical users who have already transitioned to riskier usage, the overall scale of the
benefits is limited by their relatively smaller population numbers. Our model supports a
diverse approach—interventions that impact larger populations which are at lower risk may
result in long-term benefits due to a cohort effect, and interventions that impact populations
at greater risk may save lives in the short term while we wait for long-term effects to accrue.
Study Limitations
Limitations include the complexity of the model, the scarcity of data regarding some aspects
of the overall system, which required assumptions that lack empirical support, albeit with
oversight from a knowledgeable panel. Some crucial assumptions in this model include:
•

Paying users are assumed to be socially isolated from susceptible individuals

•

Drug take-backs do not affect only those who never share their medicine, and

•

Oral Paying POA Users first tamper with POAs before switching to heroin

Another limitation is the six-year policy period. While this may seem to be a generous
length of time to evaluate the effectiveness of policy changes, it is not long enough for
cohort effects to be fully revealed. On the other hand, drug abuse and drug policy occur in a
highly dynamic environment, which tends to lessen the credibility of extrapolations beyond
a few years.
In conclusion, we believe we have provided evidence that the creation of an overall systemlevel theory of drug diversion and abuse is feasible and that such models can deepen
understanding and facilitate policy evaluation.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Simplified influence diagram of POA supply impact on POA user trajectories. Three main
feedback mechanisms impact user trajectories: Infection and Global Availability tend to
increase initiation, while Personal Accessibility tends to drive transition to paying and
riskier use.
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Figure 2.

Nonmedical POA initiation as an infection process plus initiation due to exposure by having
a prescription. Current nonmedical users may introduce peers to nonmedical use, or a person
with a prescription may initiate use outside of a social recruitment process.
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Figure 3.

Impact of informal shared “Medicine Cabinet” supply on user progression to paying POA.
People who want to use POA nonmedically “open up” the available supply by requesting
POA from friends and family, increasing available POA supply, but also consume these
medicines, thereby limiting available supply.
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Figure 4.

Initiation of nonmedical POA use and the number of Recreational Users (Using Free
Opioids). A) Model-calculated number of people initiating nonmedical POA usage over
time compared to the reference data (Mean Absolute Percentage Error = 6.6%). B) Model
calculated Recreational Users (Using Free Opioids) over time compared to reference data
(MAPE = 11.5%). Source: National Household Survey on Drug Abuse (NHSDA) 1995–
2001, NSDUH 2002–2011. (68,69)
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Figure 5.

Populations with Use Disorder. Nonmedical users with use disorder at each stage of the
progression from “Free Users with Use Disorder, to Oral ROA Paying Users to Tampering
ROA Paying Users.
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Figure 6.

A) Model calculated number of users with use disorder compared to reference data (Mean
Absolute Percentage Error = 10.7%).. Source: NHSDA1995-2001, NSDUH 2002–2011.
(3,68) B) Model-calculated number of heroin users versus reference data (MAPE = 7.9%).
Source: Office of National Drug Control Strategy 1988–2000, 2000–2006, NSDUH (2012)
(69–71)
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Figure 7.

Deaths associated with POAs and heroin vs. reference behavior (Mean Absolute Percentage
Error = 12.6%).. A) Model calculated deaths associated with nonmedical POA use vs
reference data (MAPE = 7.1%). Source: National Vital Statistics System (NVSS) 1999–
2009 (11). B) Model calculated heroin-related deaths vs. reference data. Source: NVSS
1999–2010
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Figure 8.

Impact of reduced informal sharing/leftovers and drug take-backs on A) recreational users
and B) Oral ROA Paying Users. Tampering ROA Paying Users and Heroin Users are not
shown because the model indicates that the impact of reducing the informal POAsupply
would have neglible impact on these populations over the policy period.
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Table 1

Impact of 70% tamper resistant formulations market penetration over a six-year period on prevalence and
overdose (OD) deaths

Oral ROA Paying Users
Tampering ROA Paying Users

2010

2016
baseline

2016 with
policy

1,002,000

731,000

893,000

% change
+22%

775,000

693,000

363,000

−48%

1,097,000

1,441,000

1,585,000

+10%

Total Projected OD Deaths 2011–
2016, Oral ROA Paying Users

11,020

11,880

+8%

Total Projected OD Deaths 2011–
2016, Tampering ROA Paying Users

14,370

11,850

−18%

Total Projected OD Deaths 2011–
2016, Heroin Users

17,100

17,800

+4%

Heroin Users
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Table 2

Impact of 50% reduction in leftover medicine on prevalence and overdose (OD) deaths
2010

2016
baseline

2016 with
policy

% change

Recreational Users

9,923,000

7,502,000

4,037,000

−46%

Oral ROA Paying Users

1,002,000

732,000

489,000

−33%

775,000

Tampering ROA Paying Users

693,000

683,000

−1.4%

Total Projected OD Deaths 2011–
2016, Recreational Users

23,080

18,780

−19%

Total Projected OD Deaths 2011–
2016, Oral ROA Paying Users

11,020

9,790

−11%

Total Projected OD Deaths 2011–
2016, Tampering ROA Paying
Users

14,370

14,600

+1.5%

